190 related articles for article (PubMed ID: 20111912)
1. The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.
Suzuki R; Ohtake S; Takeuchi J; Nagai M; Kodera Y; Hamaguchi M; Miyawaki S; Karasuno T; Shimodaira S; Ohno R; Nakamura S; Naoe T
Int J Hematol; 2010 Mar; 91(2):303-9. PubMed ID: 20111912
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.
Suzuki R; Murata M; Kami M; Ohtake S; Asou N; Kodera Y; Tomonaga M; Masaki Y; Kusumoto S; Takeuchi J; Matsuda S; Hirai H; Yorimitsu mS; Hamajima N; Seto M; Shimoyama M; Ohno R; Morishima Y; Nakamura S
Int J Hematol; 2003 Jun; 77(5):482-9. PubMed ID: 12841387
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.
Cruse JM; Lewis RE; Pierce S; Lam J; Tadros Y
Exp Mol Pathol; 2005 Aug; 79(1):39-41. PubMed ID: 16005710
[TBL] [Abstract][Full Text] [Related]
4. The importance of CD7 and CD56 antigens in acute leukaemias.
Tiftik N; Bolaman Z; Batun S; Ayyildiz O; Isikdogan A; Kadikoylu G; Muftuoglu E
Int J Clin Pract; 2004 Feb; 58(2):149-52. PubMed ID: 15055863
[TBL] [Abstract][Full Text] [Related]
5. CD7 expression in acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Cox C; Aronica G; Masi M; Bruno A; Simone MD; Buccisano F; Papa G
Leuk Lymphoma; 1995 Mar; 17(1-2):111-9. PubMed ID: 7539657
[TBL] [Abstract][Full Text] [Related]
6. [Clinical Features and Prognosis of 227 cases of Acute Myeloid Leukemia with Cross-lineage Antigen Expression].
Fang F; Zhu P; Zhang Y; Lu XZ; Dong YJ; Sun YH; Wang LH; Bu DF; Cen XN; Wang MJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):990-7. PubMed ID: 27531762
[TBL] [Abstract][Full Text] [Related]
7. [Immunophenotypic Analysis of Patients with CD56⁺ Acute Myeloid Leukemia].
Guo R; Shen AL; Wang Y; Liu L; Zhang JF; Wang R; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1231-4. PubMed ID: 26524014
[TBL] [Abstract][Full Text] [Related]
8. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity.
Suzuki R; Yamamoto K; Seto M; Kagami Y; Ogura M; Yatabe Y; Suchi T; Kodera Y; Morishima Y; Takahashi T; Saito H; Ueda R; Nakamura S
Blood; 1997 Sep; 90(6):2417-28. PubMed ID: 9310493
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Saito T; Usui N; Dobashi N; Maki N; Asai O; Yano S; Kato A; Watanabe H; Katori M; Nagamine M; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Kuraishi Y
Rinsho Ketsueki; 1998 Jul; 39(7):481-6. PubMed ID: 9750454
[TBL] [Abstract][Full Text] [Related]
10. Biologic and clinical significance of CD7 expression in acute myeloid leukemia.
Saxena A; Sheridan DP; Card RT; McPeek AM; Mewdell CC; Skinnider LF
Am J Hematol; 1998 Aug; 58(4):278-84. PubMed ID: 9692390
[TBL] [Abstract][Full Text] [Related]
11. Clinical and hematological correlates of aberrant immunophenotypic profiles in adult and pediatric acute myeloid leukemia at presentation.
Sharma M; Varma N; Singh Sachdeva MU; Bose P; Varma S
J Cancer Res Ther; 2020; 16(1):105-109. PubMed ID: 32362618
[TBL] [Abstract][Full Text] [Related]
12. A child case of CD34+, CD33-, HLA-DR-, CD7+, CD56+ stem cell leukemia with thymic involvement.
Nagata T; Higashigawa M; Nagai M; Zhang XL; Azuma E; Komada Y; Sakurai M
Leuk Res; 1996; 20(11-12):983-5. PubMed ID: 9009257
[TBL] [Abstract][Full Text] [Related]
13. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
14. Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia.
El-Sissy AH; El-Mashari MA; Bassuni WY; El-Swaayed AF
J Egypt Natl Canc Inst; 2006 Sep; 18(3):244-9. PubMed ID: 17671534
[TBL] [Abstract][Full Text] [Related]
15. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma.
Kita K; Miwa H; Nakase K; Kawakami K; Kobayashi T; Shirakawa S; Tanaka I; Ohta C; Tsutani H; Oguma S
Blood; 1993 May; 81(9):2399-405. PubMed ID: 7683218
[TBL] [Abstract][Full Text] [Related]
16. [The immunophenotypic analysis of CD7+ and (or) CD56+ acute myeloid leukemic stem cells and its applications in minimal residual disease detection].
Cao H; Wang YZ; Wu HH; Chang Y; Hao L; Chen SS; Huang XJ; Lu DP; Liu YR
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):23-8. PubMed ID: 18512311
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
18. The expression pattern of CD56 (N-CAM) in human bone marrow biopsies infiltrated by acute leukemia.
Khanlari B; Buser A; Lugli A; Tichelli A; Dirnhofer S
Leuk Lymphoma; 2003 Dec; 44(12):2055-9. PubMed ID: 14959847
[TBL] [Abstract][Full Text] [Related]
19. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia.
Djunic I; Virijevic M; Djurasinovic V; Novkovic A; Colovic N; Kraguljac-Kurtovic N; Vidovic A; Suvajdzic-Vukovic N; Tomin D
Med Oncol; 2012 Sep; 29(3):2077-82. PubMed ID: 22081445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
